Fresenius Medical Care (NYSE:FMS) Stock Price Expected to Rise, Truist Financial Analyst Says

Fresenius Medical Care (NYSE:FMS) had its price target boosted by Truist Financial from $23.00 to $25.00 in a report issued on Monday morning,Benzinga reports. Truist Financial currently has a hold rating on the stock.

Several other research analysts also recently issued reports on the company. Berenberg Bank started coverage on Fresenius Medical Care in a research note on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target for the company. StockNews.com assumed coverage on shares of Fresenius Medical Care in a research report on Friday, January 3rd. They set a “strong-buy” rating for the company. Finally, Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd.

Fresenius Medical Care Stock Performance

FMS opened at $22.40 on Monday. Fresenius Medical Care has a 1-year low of $17.93 and a 1-year high of $24.31. The stock has a market cap of $13.14 billion, a P/E ratio of 18.51, a P/E/G ratio of 0.95 and a beta of 0.92. The stock’s 50 day simple moving average is $22.39 and its 200 day simple moving average is $20.73. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02.

Institutional Trading of Fresenius Medical Care

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wulff Hansen & CO. boosted its stake in shares of Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after purchasing an additional 325,439 shares during the last quarter. Moran Wealth Management LLC boosted its position in Fresenius Medical Care by 47.0% during the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock worth $4,971,000 after acquiring an additional 74,621 shares during the last quarter. Quantinno Capital Management LP grew its stake in Fresenius Medical Care by 78.9% in the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after acquiring an additional 48,554 shares during the period. Franklin Resources Inc. raised its holdings in Fresenius Medical Care by 3.3% in the 3rd quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock valued at $1,490,000 after acquiring an additional 2,386 shares during the last quarter. Finally, Crossmark Global Holdings Inc. lifted its stake in shares of Fresenius Medical Care by 60.4% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock worth $1,340,000 after purchasing an additional 23,692 shares during the period. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.